No profile data available.
Cryo-Cell International, Inc. (CCEL) is a healthcare company in the biosample preservation services industry, based in Oldsmar, United States, with about 72 full-time employees.
It reported revenue of $31.57 million for fiscal year 2025, down 1.3% from fiscal year 2024, and net income of -$2.43 million. In Q2 2026 (the quarter ended May 31, 2026) revenue was $7.78 million, down 1.9% from a year before. Its largest business segment, Umbilical Cord Blood and Cord Tissue Stem Cell Service, brought in 99% of segment revenue in fiscal year 2025. Its market capitalization was $33.62 million as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended November 30, 2025; market data as of October 8, 2026.
Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States.
Cryo-Cell International reported $31.57 million in revenue for fiscal year 2025, down 1.3% from $31.99 million in fiscal year 2024. In Q2 2026 revenue was $7.78 million.
Umbilical Cord Blood and Cord Tissue Stem Cell Service, with $31.38 million or 99% of segment revenue in fiscal year 2025. Next: Public Cord Blood Banking (under 1%) and Prepacyte CB (under 1%).
$33.62 million as of October 8, 2026.
Listed companies of a similar size in the same industry (biosample preservation services) include CytoMed Therapeutics Limited (GDTC).